Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.
This study is an prospective observational real-world clinical research. We evaluated the effect of long term trimetazidine treatment after the primary percutaneous coronary intervention (PCI), the myocardial infarction size in STEMI patients could be further reduced by metabolic regulation therapy. This study contributes to the development of standardized treatment procedure for STEMI patients.
Study Type
OBSERVATIONAL
Enrollment
194
Chinese PLA general hospital
Beijing, Haidian, China
myocardial fibrosis measured by cardiac magnetic resonance imaging
Delayed enhancement of cardiac magnetic resonance imaging showed the myocardial fibrosis after infarction
Time frame: 6 months after infarction
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.